Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018

NICOLAS S. Piuzzi; M. DOMINICI; M. A.R.C. LONG; C. PASCUAL-GARRIDO; S. RODEO; J. HUARD; JÉROME GUICHEUX; R. MCFARLAND; LAURIE R. GOODRICH; STÉPHANE MADDENS; PAMELA G. ROBEY; THOMAS W. BAUER; J. O.H.N. BARRETT; F. BARRY; D. KARLI; CONSTANCE R. CHU; DANIEL J. WEISS; I. V.A.N. MARTIN; C. JORGENSEN; GEORGE F. MUSCHLER

doi:10.1016/j.jcyt.2018.09.001

Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018

NICOLAS S. Piuzzi, M. DOMINICI, M. A.R.C. LONG, C. PASCUAL-GARRIDO, S. RODEO, J. HUARD, JÉROME GUICHEUX, R. MCFARLAND, LAURIE R. GOODRICH, STÉPHANE MADDENS, PAMELA G. ROBEY, THOMAS W. BAUER, J. O.H.N. BARRETT, F. BARRY, D. KARLI, CONSTANCE R. CHU, DANIEL J. WEISS, I. V.A.N. MARTIN, C. JORGENSEN, GEORGE F. MUSCHLER

Hospital for Special Surgery

Producción científica › revisión exhaustiva

32 Citas (Scopus)

Resumen

The Signature Series Symposium “Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies—Promise, Facts and Fantasy” was held as a pre-meeting of the 26^th International Society for Cellular Therapy (ISCT) annual congress in Montreal, Canada, May 2, 2018. This was the first ISCT program that was entirely dedicated to the advancement of cell-based therapies for musculoskeletal diseases. Cellular therapies in musculoskeletal medicine are a source of great promise and opportunity. They are also the source of public controversy, confusion and misinformation. Patients, clinicians, scientists, industry and government share a commitment to clear communication and responsible development of the field. Therefore, this symposium convened thought leaders from around the world in a forum designed to catalyze communication and collaboration to bring the greatest possible innovation and value to patients with musculoskeletal conditions.

Idioma original	English
Páginas (desde-hasta)	1381-1400
Número de páginas	20
Publicación	Cytotherapy
Volumen	20
N.º	11
DOI	https://doi.org/10.1016/j.jcyt.2018.09.001
Estado	Published - nov. 2018

Financiación

The authors thanks both the ISCT and the sponsors of the First Signature Series Symposium “Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies–Promise, Facts and Fantasy,” May 2, 2018, Montreal, Canada: Greyledge Technologies (Edwards, Colorado), MTF Biologics (Edison, New Jersey), Orthofix (Lewisville, Texas), MEdXcell (Lausanne, Switzerland), Osiris Therapeutics (Columbia, Maryland) and Angiocrine Bioscience (San Diego, California). Additionally this work was supported, in part, by the DIR, NIDCR, a part of the Intramural Research Program (IRP), NIH, DHHS (to P.G.R., ZIA DE000380). The authors thanks both the ISCT and the sponsors of the First Signature Series Symposium ?Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies?Promise, Facts and Fantasy,? May 2, 2018, Montreal, Canada: Greyledge Technologies (Edwards, Colorado), MTF Biologics (Edison, New Jersey), Orthofix (Lewisville, Texas), MEdXcell (Lausanne, Switzerland), Osiris Therapeutics (Columbia, Maryland) and Angiocrine Bioscience (San Diego, California). Additionally this work was supported, in part, by the DIR, NIDCR, a part of the Intramural Research Program (IRP), NIH, DHHS (to P.G.R., ZIA DE000380).

Financiadores	Número del financiador
Angiocrine Bioscience
DIR
Intramural Research Program
National Institutes of Health
U.S. Department of Health and Human Services	ZIA DE000380
National Institute of Arthritis and Musculoskeletal and Skin Diseases	U13AR073668
National Institute of Dental and Craniofacial Research
MTF Biologics
Institut des Sciences du Cerveau de Toulouse

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Oncology
Genetics(clinical)
Cell Biology
Transplantation
Cancer Research

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.jcyt.2018.09.001

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018'. En conjunto forman una huella única.

Citar esto

Piuzzi, NICOLAS. S., DOMINICI, M., LONG, M. A. R. C., PASCUAL-GARRIDO, C., RODEO, S., HUARD, J., GUICHEUX, JÉROME., MCFARLAND, R., GOODRICH, LAURIE. R., MADDENS, STÉPHANE., ROBEY, PAMELA. G., BAUER, THOMAS. W., BARRETT, J. O. H. N., BARRY, F., KARLI, D., CHU, CONSTANCE. R., WEISS, DANIEL. J., MARTIN, I. V. A. N., JORGENSEN, C., & MUSCHLER, GEORGE. F. (2018). Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018. Cytotherapy, 20(11), 1381-1400. https://doi.org/10.1016/j.jcyt.2018.09.001

Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018. / Piuzzi, NICOLAS S.; DOMINICI, M.; LONG, M. A.R.C. et al.
En: Cytotherapy, Vol. 20, N.º 11, 11.2018, p. 1381-1400.

Producción científica › revisión exhaustiva

Piuzzi, NICOLASS, DOMINICI, M, LONG, MARC, PASCUAL-GARRIDO, C, RODEO, S, HUARD, J, GUICHEUX, JÉROME, MCFARLAND, R, GOODRICH, LAURIER, MADDENS, STÉPHANE, ROBEY, PAMELAG, BAUER, THOMASW, BARRETT, JOHN, BARRY, F, KARLI, D, CHU, CONSTANCER, WEISS, DANIELJ, MARTIN, IVAN, JORGENSEN, C & MUSCHLER, GEORGEF 2018, 'Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018', Cytotherapy, vol. 20, n.º 11, pp. 1381-1400. https://doi.org/10.1016/j.jcyt.2018.09.001

Piuzzi NICOLASS, DOMINICI M, LONG MARC, PASCUAL-GARRIDO C, RODEO S, HUARD J et al. Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018. Cytotherapy. 2018 nov.;20(11):1381-1400. doi: 10.1016/j.jcyt.2018.09.001

Piuzzi, NICOLAS S. ; DOMINICI, M. ; LONG, M. A.R.C. et al. / Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018. En: Cytotherapy. 2018 ; Vol. 20, N.º 11. pp. 1381-1400.

@article{d75aa2c2ce23464fab1d38955a318c31,

title = "Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018",

abstract = "The Signature Series Symposium “Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies—Promise, Facts and Fantasy” was held as a pre-meeting of the 26th International Society for Cellular Therapy (ISCT) annual congress in Montreal, Canada, May 2, 2018. This was the first ISCT program that was entirely dedicated to the advancement of cell-based therapies for musculoskeletal diseases. Cellular therapies in musculoskeletal medicine are a source of great promise and opportunity. They are also the source of public controversy, confusion and misinformation. Patients, clinicians, scientists, industry and government share a commitment to clear communication and responsible development of the field. Therefore, this symposium convened thought leaders from around the world in a forum designed to catalyze communication and collaboration to bring the greatest possible innovation and value to patients with musculoskeletal conditions.",

author = "Piuzzi, {NICOLAS S.} and M. DOMINICI and LONG, {M. A.R.C.} and C. PASCUAL-GARRIDO and S. RODEO and J. HUARD and J{\'E}ROME GUICHEUX and R. MCFARLAND and GOODRICH, {LAURIE R.} and ST{\'E}PHANE MADDENS and ROBEY, {PAMELA G.} and BAUER, {THOMAS W.} and BARRETT, {J. O.H.N.} and F. BARRY and D. KARLI and CHU, {CONSTANCE R.} and WEISS, {DANIEL J.} and MARTIN, {I. V.A.N.} and C. JORGENSEN and MUSCHLER, {GEORGE F.}",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = nov,

doi = "10.1016/j.jcyt.2018.09.001",

language = "English",

volume = "20",

pages = "1381--1400",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018

AU - Piuzzi, NICOLAS S.

AU - DOMINICI, M.

AU - LONG, M. A.R.C.

AU - PASCUAL-GARRIDO, C.

AU - RODEO, S.

AU - HUARD, J.

AU - GUICHEUX, JÉROME

AU - MCFARLAND, R.

AU - GOODRICH, LAURIE R.

AU - MADDENS, STÉPHANE

AU - ROBEY, PAMELA G.

AU - BAUER, THOMAS W.

AU - BARRETT, J. O.H.N.

AU - BARRY, F.

AU - KARLI, D.

AU - CHU, CONSTANCE R.

AU - WEISS, DANIEL J.

AU - MARTIN, I. V.A.N.

AU - JORGENSEN, C.

AU - MUSCHLER, GEORGE F.

PY - 2018/11

Y1 - 2018/11

N2 - The Signature Series Symposium “Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies—Promise, Facts and Fantasy” was held as a pre-meeting of the 26th International Society for Cellular Therapy (ISCT) annual congress in Montreal, Canada, May 2, 2018. This was the first ISCT program that was entirely dedicated to the advancement of cell-based therapies for musculoskeletal diseases. Cellular therapies in musculoskeletal medicine are a source of great promise and opportunity. They are also the source of public controversy, confusion and misinformation. Patients, clinicians, scientists, industry and government share a commitment to clear communication and responsible development of the field. Therefore, this symposium convened thought leaders from around the world in a forum designed to catalyze communication and collaboration to bring the greatest possible innovation and value to patients with musculoskeletal conditions.

AB - The Signature Series Symposium “Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies—Promise, Facts and Fantasy” was held as a pre-meeting of the 26th International Society for Cellular Therapy (ISCT) annual congress in Montreal, Canada, May 2, 2018. This was the first ISCT program that was entirely dedicated to the advancement of cell-based therapies for musculoskeletal diseases. Cellular therapies in musculoskeletal medicine are a source of great promise and opportunity. They are also the source of public controversy, confusion and misinformation. Patients, clinicians, scientists, industry and government share a commitment to clear communication and responsible development of the field. Therefore, this symposium convened thought leaders from around the world in a forum designed to catalyze communication and collaboration to bring the greatest possible innovation and value to patients with musculoskeletal conditions.

UR - http://www.scopus.com/inward/record.url?scp=85054715517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054715517&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2018.09.001

DO - 10.1016/j.jcyt.2018.09.001

M3 - Article

C2 - 30316562

AN - SCOPUS:85054715517

SN - 1465-3249

VL - 20

SP - 1381

EP - 1400

JO - Cytotherapy

JF - Cytotherapy

IS - 11

ER -